Molecular genotyping in medullary thyroid cancer

被引：2
|
作者：
Newbold, Kate [1 ,2 ]
机构：
[1] Royal Marsden NHS Fdn Trust Hosp, London, England
[2] Royal Marsden NHS Fdn Trust Hosp, Consultant Clin Oncologist, Fulham Rd, London SW3 6JJ, England
来源：
CURRENT OPINION IN ONCOLOGY | 2023年 / 35卷 / 01期
关键词：
medullary thyroid cancer; rearranged during transfection; ACQUIRED-RESISTANCE; RET PROTOONCOGENE; RAS MUTATIONS; CARCINOMA; ACTIVATION; SELPERCATINIB; CABOZANTINIB;
D O I：
10.1097/CCO.0000000000000915
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose of reviewThere has been a significant advance in our understanding of the molecular biology of medullary thyroid cancer (MTC) alongside progress in the development of targeted therapies including multikinase and specific rearranged during transfection inhibitors.Recent findingsThis review will examine the latest data investigating the impact of the genomics of MTC on the prediction of the natural history of an individual's disease and the determination, selection and timing of treatment interventions.Recent advances in genotyping in MTC and the development of targeted therapies have impacted on the clinical management of both sporadic and hereditary MTC.
引用
收藏
页码：10 / 14
页数：5
相关论文
共 50 条
  • [1] Update on Targeted Therapy in Medullary Thyroid Cancer
    Okafor, Christian
    Hogan, Julie
    Raygada, Margarita
    Thomas, Barbara J.
    Akshintala, Srivandana
    Glod, John W.
    Del Rivero, Jaydira
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [2] Medullary thyroid cancer-An update
    Fugazzola, Laura
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 37 (01)
  • [3] Management of Medullary Thyroid Cancer
    Viola, David
    Elisei, Rossella
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 285 - +
  • [4] VANDETANIB THERAPY IN MEDULLARY THYROID CANCER
    Grabowski, P.
    Briest, F.
    Baum, R. P.
    Zaknun, J. J.
    Kulkarni, H. R.
    Zeitz, M.
    Hoersch, D.
    DRUGS OF TODAY, 2012, 48 (11) : 723 - 733
  • [5] Molecular advances in medullary thyroid cancer diagnostics
    Hubner, Richard A.
    Houlston, Richard S.
    CLINICA CHIMICA ACTA, 2006, 370 (1-2) : 2 - 8
  • [6] Updates on therapy for medullary thyroid cancer in 2021
    Puerto, Marie
    Borson-Chazot, Francoise
    Tabarin, Antoine
    ANNALES D ENDOCRINOLOGIE, 2022, 83 (02) : 114 - 118
  • [7] Medullary Thyroid Cancer Overview and case study of a rare cancer
    Jakobs, Lynn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (02) : E37 - E43
  • [8] Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer
    Krajewska, Jolanta
    Olczyk, Tomasz
    Jarzab, Barbara
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (01) : 69 - 79
  • [9] Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?
    Kaliszewski, Krzysztof
    Ludwig, Maksymilian
    Ludwig, Bartlomiej
    Mikula, Agnieszka
    Greniuk, Maria
    Rudnicki, Jerzy
    CANCERS, 2022, 14 (15)
  • [10] A primer on the genetics of medullary thyroid cancer
    Larouche, V.
    Akirov, A.
    Thomas, C. M.
    Krzyzanowska, M. K.
    Ezzat, S.
    CURRENT ONCOLOGY, 2019, 26 (06) : 389 - 394
12345